Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry leaves poverty-related research:

This article was originally published in Clinica

Executive Summary

Industry has been discouraged from investing in research to tackle poverty-related diseases, such as malaria, tuberculosis and AIDS, because of the lack of returns. It is now up to the European Community to fill this gap by giving its financial support, EU Research Commissioner Philippe Busquin has said. Speaking at the launch of the European Commission's programme of clinical trials for poverty-related diseases he said that the programme will improve the impact of public investment by allowing a more coherent and targeted approach. He added that the clinical trials programme will help create a critical mass of research competence and establish a more structured partnership. The European Community is allocating E200 million ($182 million) to the programme over five years under the Sixth Framework Programme for research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT066532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel